STOCK TITAN

Exact Sciences Corp - EXAS STOCK NEWS

Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.

Exact Sciences Corporation (EXAS) delivers innovative cancer diagnostics through products like Cologuard® and Oncotype DX®. This page provides investors and healthcare professionals with essential updates on the company’s advancements in early cancer detection.

Find curated press releases and news covering financial results, regulatory milestones, product innovations, and strategic partnerships. Our repository ensures timely access to developments impacting precision oncology and noninvasive screening technologies.

Stay informed about EXAS’ role in molecular diagnostics, including updates on clinical studies, technology licensing agreements, and market expansion efforts. All content is verified for accuracy and relevance to support informed decision-making.

Bookmark this page for streamlined access to Exact Sciences’ latest developments. Check back regularly for authoritative updates directly affecting the future of cancer screening and diagnostic solutions.

Rhea-AI Summary
Exact Sciences Corp. selected for ComboMATCH clinical trials to analyze tumor samples using OncoExTra test
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
-
Rhea-AI Summary
New research reveals barriers to colorectal cancer screening among 45-year-olds in the US
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. reports record results for the second quarter of 2023, with total revenue of $622 million, an increase of 19%. The company also generated positive free cash flow of $66 million and raised its full-year revenue and adjusted EBITDA guidance. Exact Sciences anticipates revenue of $2.441-$2.466 billion for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.73%
Tags
Rhea-AI Summary
Exact Sciences Corp. plans to release its second quarter 2023 financial results on August 1, 2023. The company will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. announced positive top-line results from the pivotal BLUE-C study, showing that next-generation Cologuard met all study endpoints and improved every top-line metric. The results include a 30% lower false positive rate compared to the FDA registrational trial for Cologuard. The study reflects the racial and ethnic diversity of the U.S. with 20,000 participants. The company plans to complete FDA submission for next-generation Cologuard by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
none
Rhea-AI Summary
Exact Sciences Corp. has been certified as a 2023 Great Place To Work® for the fifth consecutive year. This year, 82% of Exact Sciences employees said that it is a Great Place To Work, surpassing the average U.S. company by 25 points. The certification is based on a confidential survey open to U.S.-based employees, evaluating the company's work environment, culture, and leadership. Great Place To Work is known for delivering market-leading revenue, employee retention, and increased innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
conferences
-
Rhea-AI Summary
Exact Sciences to present new data confirming approach to multi-cancer early detection, real-world outcomes using Oncotype DX Breast Recurrence Score, and modeling comparisons between Cologuard and blood-based tests for colorectal cancer at ASCO Annual Meeting 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none
Exact Sciences Corp

Nasdaq:EXAS

EXAS Rankings

EXAS Stock Data

8.22B
183.06M
1.07%
100.78%
5.74%
Diagnostics & Research
Services-medical Laboratories
Link
United States
MADISON